Correlation Between Visa and ANI Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Visa and ANI Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and ANI Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Visa Class A and ANI Pharmaceuticals, you can compare the effects of market volatilities on Visa and ANI Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of ANI Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and ANI Pharmaceuticals.

Diversification Opportunities for Visa and ANI Pharmaceuticals

0.41
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Visa and ANI is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and ANI Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ANI Pharmaceuticals and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with ANI Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ANI Pharmaceuticals has no effect on the direction of Visa i.e., Visa and ANI Pharmaceuticals go up and down completely randomly.

Pair Corralation between Visa and ANI Pharmaceuticals

Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.63 times more return on investment than ANI Pharmaceuticals. However, Visa Class A is 1.58 times less risky than ANI Pharmaceuticals. It trades about 0.06 of its potential returns per unit of risk. ANI Pharmaceuticals is currently generating about -0.24 per unit of risk. If you would invest  31,470  in Visa Class A on September 28, 2024 and sell it today you would earn a total of  337.00  from holding Visa Class A or generate 1.07% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy95.24%
ValuesDaily Returns

Visa Class A  vs.  ANI Pharmaceuticals

 Performance 
       Timeline  
Visa Class A 

Risk-Adjusted Performance

18 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Visa Class A are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Visa showed solid returns over the last few months and may actually be approaching a breakup point.
ANI Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ANI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, ANI Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Visa and ANI Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Visa and ANI Pharmaceuticals

The main advantage of trading using opposite Visa and ANI Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, ANI Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will offset losses from the drop in ANI Pharmaceuticals' long position.
The idea behind Visa Class A and ANI Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins